Back to Results
First PageMeta Content
Pharmaceutical industry / Clinical Data Management / Drug safety / European Medicines Agency / Electronic Common Technical Document / Pharmacovigilance / EMA / CD-ROM / Compact Disc / Clinical research / Research / Pharmaceutical sciences


NCAs and EMA requirements for submission of PSUR during the transitional period
Add to Reading List

Document Date: 2014-08-08 06:31:29

Open Document

File Size: 242,85 KB

Share Result on Facebook

City

DUBLIN / RIGA / NICOSIA / Sofia / Budapest / Zagreb / London / /

Company

Health / /

Country

Germany / Croatia / Cyprus / Latvia / United Kingdom / Czech Republic / /

/

Facility

Federal Institute / State Institute / Canary Wharf / National Institute of Pharmacy / Holargos Greece National Institute of Pharmacy Zrinyi / /

IndustryTerm

e-submission / authorised product / medicinal products / medicinal product / authorised products / /

Organization

Federal Agency for Medicines and Health Products / Institut Pharmakovigilanz Traisengasse / Belgian Centre / Holargos Greece National Institute of Pharmacy Zrinyi / State Agency of Medicines / PRAC and CHMP / Federal Institute for Drugs and Medical Devices / Committee for Medicinal Products for Human Use / The Danish Health and Medicines Authority Division of Pharmacovigilance / Irish Medicines Board / EMA Management Board / CHMP / National Organization / Medical Devices / State Institute for Drug Control Šrobárova / European Medicines Agency / Bulgarian Drug Agency / Paul Ehrlich Institut / Medicines Administration Unit General Secretariat / National Institute of Pharmacy / European Union / Ministry of Health / /

Person

Paul Ehrlich / Roberta Frangeša Mihanovića / DENIS CEDEX / Axel Heides Gade / Victor Horta / /

/

Position

Governor / Registrar / /

ProgrammingLanguage

DC / /

ProvinceOrState

Hessen / /

RadioStation

1 When / /

Technology

PDF / /

URL

http /

SocialTag